NF-κB (Nuclear Factor Kappa B)
A transcription factor that regulates genes involved in inflammation, immunity, and cell survival. CBD inhibits NF-κB activation, contributing to its anti-inflammatory effects.
In Depth
NF-κB is a master regulator of inflammation — it controls the expression of over 150 genes including TNF-α, IL-1β, IL-6, COX-2, and iNOS. Chronic NF-κB activation drives inflammatory diseases, autoimmunity, and cancer. CBD inhibits NF-κB through multiple mechanisms including PPAR-γ activation and direct inhibition of IκB kinase. This NF-κB inhibition contributes to CBD's anti-inflammatory effects in models of neuroinflammation, IBD, and arthritis.
Related Terms
More in Pharmacology
Endocannabinoid System (ECS)
A lipid-based retrograde neurotransmitter system comprising endogenous cannabinoids (endocannabinoids), their receptors (CB1, CB2), and metabolic enzymes.
CB1 Receptor
Cannabinoid receptor type 1. A G protein-coupled receptor (GPCR) primarily expressed in the central nervous system. The primary target of THC's psychoactive effects.
CB2 Receptor
Cannabinoid receptor type 2. A GPCR primarily expressed in immune tissues and peripheral organs. Less abundant in the CNS than CB1.
Anandamide (AEA)
N-arachidonoylethanolamine. The first endocannabinoid identified. A partial agonist at CB1 and CB2 receptors, named from the Sanskrit word "ananda" meaning bliss.
2-Arachidonoylglycerol (2-AG)
The most abundant endocannabinoid in the brain. A full agonist at both CB1 and CB2 receptors.